Ghaziabad
Open Emergency Modal

Immunotherapy in Ghaziabad

Immunotherapy has transformed cancer treatment over the past decade by helping the body's own immune system recognise and attack cancer cells. Unlike conventional treatments that directly target cancer cells, immunotherapy works by strengthening or modifying the immune response to fight the disease.

For certain cancers, such as advanced melanoma, immunotherapy has significantly improved outcomes that were once difficult to achieve with chemotherapy alone. However, it is not suitable for every type of cancer or every patient. The effectiveness of immunotherapy depends on factors such as the type of cancer, its stage, and specific biological characteristics of the tumour.

This guide explains the concept of cancer immunotherapy, its different types including CAR T-cell therapy, how immunotherapy differs from chemotherapy, possible side effects, and the immunotherapy treatment options available through the Yashoda Medicity oncology department in Ghaziabad.

What Is Cancer Immunotherapy?  

Cancer immunotherapy is a type of treatment that helps the body's own immune system recognise and destroy cancer cells. Unlike chemotherapy and radiation therapy, which directly target cancer cells, immunotherapy works by stimulating, strengthening, or guiding the immune response against cancer.

Cancer cells often develop mechanisms that allow them to escape detection by the immune system. They may produce certain proteins or signals that prevent immune cells from attacking them. Immunotherapy helps overcome these defence mechanisms, allowing the immune system to identify and target cancer cells more effectively.

Types Of Immunotherapy For Cancer  

Immunotherapy includes several types of treatments that work through different mechanisms:

  • Immune checkpoint inhibitors – These are among the most commonly used immunotherapy medicines today. They block proteins such as PD-1, PD-L1, or CTLA-4 that normally act as immune system "brakes." By blocking these checkpoints, they allow immune cells to recognise and attack cancer cells more effectively.
  • CAR T-cell therapy – This is a personalised form of immunotherapy in which a patient's own immune cells (T cells) are modified in a laboratory to recognise specific proteins (antigens) on cancer cells and destroy them. It is mainly used for certain blood cancers.
  • Monoclonal antibodies – These are laboratory-made antibodies designed to identify specific targets on cancer cells or help the immune system attack them. Some monoclonal antibodies, such as rituximab, are used in the treatment of certain lymphomas and work partly through immune-mediated mechanisms.
  • BCG and cancer vaccines – BCG is a type of immunotherapy that is administered directly into the bladder to treat certain early-stage bladder cancers. It stimulates a local immune response that helps reduce the risk of cancer recurrence. It remains one of the oldest and most established forms of cancer immunotherapy.
  • Cytokine therapy – These are older immune-based treatments, such as interleukin-2 (IL-2) and interferons, which help activate immune responses. They are used selectively today, mainly in certain cases of melanoma and kidney cancer.

Immunotherapy Vs. Chemotherapy  

Although both chemotherapy and immunotherapy are used to treat cancer, they work in very different ways. Chemotherapy uses medicines that directly attack rapidly dividing cells, including cancer cells. Since some healthy cells also divide quickly, such as hair follicle cells and blood-producing cells, chemotherapy can cause side effects such as hair loss, fatigue, and changes in blood counts.

Immunotherapy does not directly destroy cancer cells. Instead, it helps the body's immune system recognise and attack cancer cells more effectively. Because it activates the immune response, its side effects are usually related to immune system overactivity rather than direct damage to healthy cells.

The timing and pattern of side effects can also differ. Chemotherapy-related side effects often appear soon after treatment, while immune-related side effects from immunotherapy may occur later during treatment or even after treatment has ended. In some cases, imaging scans may show temporary tumour enlargement, known as pseudo-progression, due to immune cells entering the tumour rather than actual cancer growth.

Chemotherapy and immunotherapy are not always alternatives. In many cancers, including certain types of lung and breast cancers, a combination of both treatments may be recommended because they work through different and complementary mechanisms.

Immunotherapy For Melanoma 

Melanoma has been one of the most significant success stories in the development of cancer immunotherapy. In advanced (metastatic) melanoma, outcomes were historically poor with conventional treatments alone.

Immune checkpoint inhibitors, either used individually or in combination, have significantly improved outcomes for many patients with advanced melanoma. A combination of a PD-1 inhibitor and a CTLA-4 inhibitor may be recommended in certain advanced cases, depending on the patient's condition and treatment suitability. These therapies can produce long-lasting responses in a proportion of patients.

Immunotherapy For Bladder Cancer  

Immunotherapy has an established role in bladder cancer, with treatment options depending on the stage and characteristics of the disease.

One of the earliest and most effective uses of immunotherapy in cancer care is BCG therapy for non-muscle invasive bladder cancer. BCG is administered directly into the bladder after surgical removal of the tumour to stimulate a local immune response and reduce the risk of recurrence.

Checkpoint inhibitors are another important immunotherapy option for advanced or metastatic bladder (urothelial) cancer, particularly in selected patients who may not be suitable candidates for chemotherapy or whose cancer has specific characteristics that make them more likely to respond.

Immunotherapy For Breast Cancer  

The role of immunotherapy in breast cancer is more specific compared with cancers such as melanoma or bladder cancer. Its use depends largely on the biological characteristics of the tumour. Checkpoint inhibitors are primarily used in certain cases of triple-negative breast cancer (TNBC), particularly when the tumour shows PD-L1 expression. They are generally given in combination with chemotherapy rather than as standalone treatment in most cases.

Hormone receptor-positive and HER2-positive breast cancers, which represent the majority of breast cancer cases, are usually treated with hormone therapy or HER2-targeted therapies respectively. Therefore, the role of immunotherapy in breast cancer is determined through detailed pathology and biomarker testing.

Identifying Candidates For Immunotherapy 

Not every patient with cancer is suitable for immunotherapy. Eligibility depends on the type of cancer, its stage, previous treatments, and specific characteristics of the tumour. Biomarker testing performed on tumour tissue obtained through a biopsy helps doctors determine whether immunotherapy may be beneficial. Tests may include PD-L1 expression, tumour mutational burden (TMB), microsatellite instability (MSI), or other molecular markers depending on the type of cancer.

These tests have become an important part of treatment planning for many cancers because they help identify patients who are more likely to respond to immunotherapy. For CAR T-cell therapy, eligibility depends on factors such as the type of blood cancer, previous treatments received, overall health condition, and suitability for the preparation process required before therapy.

Immunotherapy Side Effects 

Since immunotherapy activates the immune system, its side effects are different from the typical side effects associated with chemotherapy. These effects are known as immune-related adverse events and occur when the immune system becomes overactive and starts affecting healthy tissues.

Patients should report any new or unusual symptoms during treatment, as early identification and management can help prevent complications.

Common immune-related side effects include:

  • Skin effects – Rash, itching, and other skin reactions.
  • Gastrointestinal effects – Diarrhoea or colitis (inflammation of the colon).
  • Lung effects – Pneumonitis (inflammation of lung tissue), which may cause cough or shortness of breath.
  • Endocrine effects – Inflammation of hormone-producing glands, including the thyroid, adrenal glands, or pancreas, which may sometimes require long-term hormone replacement therapy.
  • Liver effects – Hepatitis (liver inflammation), which may not cause symptoms initially and is often detected through blood tests.
  • Serious but rare side effects – Myocarditis (inflammation of the heart muscle), which requires prompt medical attention.

Most immune-related side effects can be managed effectively when identified early. Treatment may include corticosteroids, temporary interruption of immunotherapy, or other supportive measures depending on the severity of symptoms. Regular monitoring throughout treatment is an important part of safe immunotherapy care.

Why Choose Yashoda Medicity For Immunotherapy In Ghaziabad?

At Yashoda Medicity, immunotherapy treatment is planned based on the specific characteristics of each patient's cancer. A multidisciplinary approach helps determine the most appropriate treatment strategy while ensuring close monitoring throughout the treatment journey.

  • Molecular and genetic testing – Relevant biomarker testing, including PD-L1 and other tumour-specific markers, helps determine whether immunotherapy may be suitable for a particular cancer.

  • Cell and Gene Therapy Lab – Advanced facilities supporting treatment options such as CAR T-cell therapy for eligible blood cancer patients.

  • Multidisciplinary tumour board approach – Treatment planning involving experts from medical oncology, hemato-oncology, uro-oncology, and gynaecologic oncology, considering the varied applications of immunotherapy across cancer types.

  • Structured monitoring protocols – Regular assessment and management of immune-related side effects throughout treatment.

  • Day-care infusion facilities – A complete immunotherapy care pathway available locally in Ghaziabad.

Book a Consultation  

If you would like to understand whether immunotherapy is suitable for your specific cancer diagnosis or need a second opinion on a recommended treatment plan, our oncology team can guide you based on your cancer type, biomarker test results, and overall health condition.

To book a consultation at Yashoda Medicity, Ghaziabad, call +91 9266610101 or use the online booking form available on this page.

Yashoda Medicity, Hospital Plot, Shakti Khand 2, Indirapuram, Ghaziabad, Uttar Pradesh - 201014  |  Phone: +91 9266610101

Meet Our Expert Medical Team

Dr. Jigar Paghadar
Dr. Jigar Paghadar

Junior Consultant

Dr. Nikhil Tandon
Dr. Nikhil Tandon

Consultant

Dr. Nishtha Sachdeva
Dr. Nishtha Sachdeva

Consultant

Dr. Manish Singhal
Dr. Manish Singhal

Vice Chairman

Dr. Nivedita Dhingra
Dr. Nivedita Dhingra

Director & Head

Dr. Karuna Jha
Dr. Karuna Jha

Senior Consultant

Dr. Hemlata Garg
Dr. Hemlata Garg

Consultant

Dr. Ipshita Sahoo
Dr. Ipshita Sahoo

Associate Consultant

Dr. Satinder Kaur
Dr. Satinder Kaur

Senior Director and Head

Dr. Abhishek Yadav
Dr. Abhishek Yadav

Director

Dr. Gagan Saini
Dr. Gagan Saini

Vice-Chairman & Head

Dr. Rashmi Shukla
Dr. Rashmi Shukla

Principal Consultant

Our Technological Advancements

Patient Testimonials

Frequently Asked Questions

Neither treatment is universally better than the other. Chemotherapy and immunotherapy work differently and are used depending on the type of cancer, its stage, and individual patient factors. In many cases, both treatments may be used together as part of a comprehensive cancer treatment plan.

No. Immunotherapy has an established role in several cancers, including melanoma, lung cancer, bladder cancer, kidney cancer, and certain blood cancers. In other cancers, such as triple-negative breast cancer, its role is more specific and depends on factors such as biomarker results.

Common side effects include skin rash, itching, diarrhoea or colitis, fatigue, and endocrine-related effects such as thyroid changes. Unlike chemotherapy-related side effects, immune-related side effects can occur at different stages of treatment and may sometimes appear even after treatment has ended.

Yes. BCG therapy for bladder cancer is one of the oldest and most established forms of cancer immunotherapy. It is administered directly into the bladder to stimulate an immune response that helps reduce the risk of cancer recurrence.

The suitability of immunotherapy depends on your cancer type, tumour characteristics, and biomarker test results. Your oncologist will evaluate these factors to determine whether immunotherapy may be an appropriate treatment option. To schedule a consultation, call +91 9266610101.

Main Speciality


Speciality in Location